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Abstract 
The purpose of this research work was to develop oral sustained 
release matrix tablets using the combination of HPMC 4000 cps 
(methocel K4M CR) and xanthan gum (3:1), in order to probe the 
effect of these polymers on release mechanism from matrix tablets. 
The matrix tablets of Ketotifen fumarate were prepared by direct 
compression process using methocel K4M CR and xanthan. The 
dissolution profiles were carried out by USP apparatus 2 (paddle) at 
50 rpm in 500 ml 0.1 N HCl and distilled water. A One way analysis 
of variance (ANOVA) was used to interpret the result. Statistically 
significant differences were found among the drug release profile 
from different matrices. At a higher polymeric content (70% of the 
total tablet weight), drug release from the combination of methocel 
K4M CR and xanthan gum (3:1) was slower. On the contrary, at a 
lower polymeric level (40% of the total tablet weight), the rate of 
drug release was prominent. The best-fit release kinetics was 
accomplished with the Higuchi model followed by the zero-order 
plot, Korsmeyer and Hixson Crowell equations. One formulation 
showed drug release is more controlled. The data obtained proved 
that the formulations are useful for a sustained release of ketotifen 
fumarate. From these formulations corresponded more controlled of 
the drug release by the higher polymeric level of methocel K4M CR 
& xanthan and vice versa. The release of the model drug from the 
higher combination of methocel K4M CR and xanthan gum  matrix 
tablets was prolonged. As a result, an oral release dosage form to 
evade the frequency of administration of such type of drug. 
Keywords: Ketotifen Fumarate, HPMC, Xanthan gum, Matrix 
tablets, Sustained Release. 
 
Introduction 
Oral ketotifen is indicated as an add-on 
medication in the chronic treatment of mild 
atopic asthmatic children. Ketotifen is a 
prophylactic agent to be used on a continuous 
basis and is not effective in the acute prevention 
or treatment of acute asthma attacks [1]
.
 
Ketotifen fumarate has the properties of the 
antihistamines in addition to a stabilizing action 
on mast cells analogous to that of sodium 
cromoglycate. It is given orally as the fumarate in 
the prophylactic management of asthma, and also 
used in the treatment of allergic conditions such 
as rhinitis and conjunctivitis. Ketotifen fumarate 
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is taken by mouth in dose equivalent to 1mg of 
Ketotifen twice a daily with food [2] Relatively 
selective histamine H1-receptor antagonist and 
mast-cell stabilizer [3]. Both ketotifen and 
inhaled budesonide are effective, safe, and well-
tolerated in the prevention of asthma 
exacerbation in children particularly in the 
country with limited resource [4]
.
 Ketotifen 
fumarate, 4,9-dihydro-4-(1-methyl -4 -
piperidinylidene) -10 -H -benzo cycloheptal-,2-b 
thiophen-10-one fumarate, is used as an 
antiasthamatic agent [5].
 
 
The development of controlled release systems of 
antiasthmatic antianaphylactic drugs is expected 
to grow significantly, to avoid acute over dosage. 
Ketotifen is a perfect candidate for the 
development of controlled release systems of 
antiasthmatic antianaphylactic compounds. Its 
acute toxicity is rather low, since no serious 
effects have been reported either in children or in 
adults after the intake of up to 20 mg of ketotifen, 
which is 10 times the recommended dose and it is 
well tolerated specially by the children. Ketotifen 
also induces a moderate to marked symptom 
improvement in the majority of patients with 
atopic dermatitis, seasonal or perennial rhinitis, 
allergic conjunctivitis, chronic or acute urticaria 
[6-7]
. 
 
The sorption of water in the both cellulose acetate 
propionate and cellulose acetate butyrate 
membranes is quite similar and that the release 
characteristics of these systems do not follow a 
zero order profile, indicating that the diffusion 
mechanism may be Fickian, controlled mainly by 
the membrane morphology [8]
. 
 
Hydrophilic polymers are widely used in the 
formulation of sustained release oral dosage 
forms. Various natural materials (xanthan, guar 
gum, and chitosan) have been tried by various 
researchers. It has been shown that in hydrophilic 
matrices, swelling as well as erosion of the 
polymer occurs simultaneously, and both of them 
contribute to the overall drug release rate [9]. 
Xanthan gum is a high molecular weight 
extracellular polysaccharide produced by the 
fermentation of the Gram-negative bacterium 
Xanthomonas campestris. Xanthan gum offers 
potential utility as a drug carrier because of its 
inertness and biocompatibility. 
 
Xanthan gum not only retards in vitro drug 
release and provides time independent release 
kinetics, but also works effectively in vivo and 
establishes constant drug plasma levels [10]. 
Dhopeshwarkar and Zatz evaluated xanthan gum 
as a matrix former for the preparation of 
sustained-release tablets. It was very effective in 
prolonging the release of soluble and sparingly 
soluble drugs [11].  
 
Hydrophillic polymer matrix systems are widely 
used in oral controlled drug delivery systems 
because of their flexibility to obtain a desirable 
drug release profile, cost effectiveness, and broad 
regulatory acceptance [12]. Drug release from 
hydrophillic matrices is known to be a complex 
interaction between dissolution, diffusion and 
erosion mechanisms. Hydroxypropyl 
methylcellulose (HPMC) is the first choice for 
formulation of hydrophilic matrix system, 
providing robust mechanism, choice of viscosity 
grades, nonionic nature, consistent reproducible 
release profiles, cost effectiveness and utilization 
of existing conventional equipment and methods 
[13]. Water penetration, polymer swelling, drug 
dissolution, drug diffusion and matrix erosion 
from dosage form is controlled by the hydration 
of HPMC, which forms the gel barrier through 
which the drug diffuses. 
 
Direct compression was used to compress the 
tablets, as keeping in mind that HPMC is a 
hydrophillic polymer that swells to a significant 
extent upon contact with water. Various studies 
of drug release mechanism, effect of formulation 
variables on HPMC matrices are based on direct 
compression [14,15]. 
 
Thus, the purpose of this investigation was to 
study processing variables at the laboratory and 
pilot scales that can affect hydration rates of 
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methocel K4M CR and xanthan gum matrices 
containing ketotifen fumarate and hence rate of 
drug release. 
 
Materials and Methods 
Materials 
Ketotifen fumarate was obtained as gift sample 
from Beximco Pharmaceuticals Ltd. Dhaka, 
Bangladesh. HPMC 4000 cps (methocel K4M 
CR) was a gift sample received from Colorcon 
Asia Pvt.Limited. Lactose was purchased from 
Ming Tai Chemical Co.Ltd., (Taiwan). Xanthan 
gum was procured from Loba chemical, India. 
Magnesium stearate and Talc were procured from 
Hanua Chemicals Limited, (Japan).  
 
Preparation of Matrix Tablets 
Tablets were prepared by direct compression 
process. In all cases, the amount of the active 
ingredient was 2.75 mg and the total weight of 
the tablet was 150 mg (Table-1).  
  
During granulation process matrix-forming 
agents, HPMC 4000 cps (methocel K4M CR) & 
Xanthan gum, magnesium stearate, lactose, talc 
and the active ingredient were weighed properly. 
Firstly active ingredient, talc and HPMC 4000 
cps (methocel K4M CR) and Xanthan gum (3:1) 
were mixed for 10 minutes properly. Dried 
granules were sieved through 20 mesh SS screen 
to get compressible particle. Lubricants are added 
during blending part. During blending total mass 
was taken in a container and blended in a 
laboratory designed small drum blender machine 
for about 30 minutes. Particular attention was 
given to ensure thorough mixing and phase 
homogenization. The appropriate amount of the 
mixture were accurately weighed in an electronic 
balance for the preparation of each tablet and 
finally compressed using single station 
compression machine,  with a 8.00 mm punch. 
Before compression, the surfaces of the die and 
punch were lubricated with purified talc. All the 
preparations were stored in airtight containers at 
room temperature for further study. 
 
Physical characterization of matrix 
tablets 
The tablets of the proposed formulations (KF1 to 
KF4) were evaluated for hardness, weight 
variation, thickness, friability and drug content. 
Hardness of 10 matrix tablets from each 
formulation was measured using Hardness tester 
(Erweka GMBH, 300H model, Germany). 
Friability of the tablets was determined by testing 
10 tablets in a Roche friabilator (Campbell 
Electronics, Mumbai) for 4 minutes at 25 rpm 
performed in triplicate. A slide calipers was used 
to measure the thickness for 5 tablets.  Weight 
variation test was performed by taking 10 tablets 
using an electric balance (OHAUS LS 200, 
Switzerland) according to the official method.
 
Table 1. Formulation of methocel K4M CR and xanthan gum (3:1) based Ketotifen fumarate sustained 
release matrices. 
Formulation 
Code 
Ketotifen 
fumarate 
Methocel 
K4M CR  
Xanthan 
Gum Lactose  
Mag. 
stearate Talc 
(mg/tablet) 
KF1 2.75 45 15 85.25 0.5 1.5 
KF2 2.75 56.25 16.75 70.25 0.5 1.5 
KF3 2.75 67.5 22.5 55.25 0.5 1.5 
KF4 2.75 78.75 26.25 40.75 0.5 1.5 
        Compression weight of each formulation was 150 mg. 
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Drug content for Ketotifen fumarate was carried 
out by measuring the absorbance of the sample at 
300 nm using Shimadzu 1240 UV visible 
spectrophotometer, Japan and comparing the 
content from a calibration curve prepared with 
standard Ketotifen fumarate in the same medium 
by taking 20 tablets were taken, weighed and 
finely powdered. An accurately weighed quantity 
of this powder was taken, suitably dissolved in 
distilled water, making dilution and analyzed and 
carried out in triplicate and mean was taken. 
 
In Vitro Drug Dissolution Studies 
Drug release profiles were evaluated in vitro 
using a dissolution test apparatus (VEEGO VDA 
8 DR, Germany). The USP paddle method was 
selected to perform the dissolution profiles of 
Ketotifen fumarate. The test for all the 
formulations was carried out in 500 ml 0.1 N 
HCl, and distilled, maintained at 37.5 0C (± 
0.5°C) at a paddle rotation speed of 50 rpm. 
Withdrawing 5 ml filtered samples at preselected 
intervals up to 8 hours monitored progress of the 
dissolution. The release rates from these 
polymeric matrices were conducted in a medium 
of changing pH by starting with a tablet in HCl 
solution (pH=1.2) for 2 hours. Then, the tablets 
were immersed into a distilled for next 6 hours. 
The sample solutions were analyzed for Ketotifen 
fumarate by UV absorbance at 300 nm using a 
UV Spectrophotometer (UV-1240 mini, 
SHIMADZU, Japan). Cumulative percentage of 
drug release was calculated and the mean of six 
tablets was used in data analysis.  
 
Release Kinetics 
Different kinetic models (zero-order, first-order, 
Higuchi’s, Korsmeyer’s and Hixson Crowell) 
were applied to interpret the release profile (the 
order and mechanism of Ketotifen fumarate 
release) from matrix system. To study the 
mechanism of drug release from the matrix 
tablets, the release data were fitted to zero-order, 
first-order, and Higuchi equation. However, two 
factors diminish the applicability of Higuchi’s 
equation to matrix systems. This model fails to 
allow the influence of swelling of the matrix 
(upon hydration) and gradual erosion of the 
matrix. Therefore, the dissolution data were also 
fitted according to the well-known exponential 
equation (Korsmeyer equation), Eq. (1), which is 
often used to describe the drug release behavior 
from polymeric systems.  
 
Log (Mt / Mf) = Log k + n Log t  …………. (1) 
 
Where, Mt is the amount of drug release at time t; 
Mf is the amount of drug release after infinite 
time; k is a release rate constant incorporating 
structural and geometric characteristics of the 
tablet; and n is the diffusional exponent 
indicative of the mechanism of drug release. 
Talukder et al [16] applied this equation to 
evaluate the drug release mechanism from 
xanthan gum matrix tablets. To clarify the release 
exponent for different batches of matrix tablets, 
the log value of percentage drug dissolved was 
plotted against log time for each batch according 
to the equation 1. A value of n = 0.45 indicates 
Fickian (case I) release; >0.45 but <0.89 for non-
Fickian (anomalous) release; and >0.89 indicates 
super case II type of release. Case II generally 
refers to the erosion of the polymeric chain and 
anomalous transport (non-Fickian) refers to a 
combination of both diffusion and erosion 
controlled-drug release [17].  
The Hixson - Crowell cube root equation is: 
 
M1/3 = Mo1/3 – Kct --------------------------------- (2)   
 
Where, Kc is the cube root dissolution rate 
constant. Cube roots of percent releases (Cube 
root of initial drug load minus cube root of % 
drug remaining) are plotted against time (hour) to 
demonstrate the Hixson Crowell plot. 
Mean dissolution time (MDT) was calculated 
from dissolution data using the following 
equation [18].   
 
MDT= (n / n+1).K -1/n ……………. (3) 
 
Statistical Analysis:  
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A one way analysis of variance (ANOVA) was 
used to analyze the dissolution data obtained for 
each batch of formulation to compare the drug 
release rate and comparison of mean dissolution 
time (MDT) of all formulations. A confidence 
limit of P < .05 was fixed and the theoretical 
calculated values of F (Fcrit and Fcal) were 
compared for the interpretation of results. 
ANOVA was determined using SPSS software 
(Version 12, SPSS Inc., USA). 
 
Results  
Physical Evaluation of Ketotifen fumarate 
matrix tablets 
The tablets of the proposed formulations (KF1 to 
KF4) were evaluated for hardness, weight 
variation, thickness, friability and drug content. 
The thickness (mean ± SD, n=5) of the tablets 
were (3.75±0.01, 3.50±0.02, 4.00±0.03, 
3.99±0.02 respectively) ranged from 3.5 to 4.00 
mm. The hardness (mean ± SD, n=10) and 
percentage friability (< 1%) of the tablets of all 
batches (5.50±0.27, 4.70±0.3, 5.50±0.27, 
4.90±0.4 respectively) ranged from 4.70 to 5.5 
kg/cm2 and 0. 45% to 0.66 %, respectively. The 
average percentage weight deviation of 10 tablets 
of each formula was less than ± 5%. Drug content 
(mean value ± SD within 0.9) among different 
batches of tablets ranged from 150.50 mg to 
151mg.  
 Effect of HPMC 4000 cps (methocel K4M CR) 
and Xanthan gum on release pattern of 
Ketotifen fumarate 
Matrix tablets of Ketotifen fumarate were 
formulated using direct compression technique. 
Different proportion of HPMC 4000 cps 
(Hydroxypropylmethylcellulose 4000 cps) and 
xanthan gum (3:1) matrix tablet containing 
Ketotifen fumarateas active ingredient having 
methocel K4M CR and xanthan gum polymer 
(3:1)  containing 40%, 50%, 60% and 70%  in the 
matrix tablet with the formulation code KF1, 
KF2, KF3, KF4 were prepared to evaluate the 
effect of these polymer. After preparation 
according to formulation shown in the table 1, 
their dissolution studies were carried out in 
basket method at 50 rpm in 500ml, distilled water 
medium at 37 0C (±0.50C). Six tablets from each 
formulation were used in dissolution study. The 
release profile of Ketotifen fumarate was 
monitored up to 8 hours (Initial 2 hours in 
simulated gastric fluid (pH 1.2) and next 6 hours 
in distilled water).  
 
A release profile of Ketotifen fumaratecontaining 
having HPMC 4000 cps (methocel K4M CR) and 
xanthan gum polymer (3:1) polymeric  matrix 
tablets of the formulations was obtained from the 
graphs (Fig. 1A- 1E).  
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Fig. 1A: Zero order plot of release kinetics of Ketotifen fumarate matrix tablets. 
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Fig.1B: Higuchi plot of release kinetics of Ketotifen fumarate matrix tablets. 
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Fig. 1C: First order plot of release kinetics of Ketotifen fumarate matrix tablets. 
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Fig. 1D: Korsmeyer plot of release kinetics of Ketotifen fumarate matrix tablets. 
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Fig. 1E: Hixson Crowell plot of release kinetics of Ketotifen fumarate matrix tablets. 
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The total % of Ketotifen fumarate release (mean 
value ± SD within 0.7, n = 6) from the 
formulations KF1, KF2, KF3, KF4 was 77.060, 
61.910, 51.760, 49.005 respectively. It has been 
observed that the release rate has been extended 
with the increase of the amount of polymeric 
level. The highest percent of drug release within 
8 hours is 77.060% obtained from KF1 where 
methocel K4M CR and xanthan gum polymer 
(3:1) amount of polymeric level is lower 40%.  
But in KF4 (methocel K4M CR and xanthan 
gum) containing amount of polymeric level is 
higher 70% and the release of drug is 49.005% 
within 8 hours. The rate of drug release was 
found to be inversely related to proportion of the 
polymer present in the matrix structure, i.e. the 
drug release increased with lower viscosity grade 
and polymer proportion in the matrix tablet. The 
release rate was significantly dependent on the 
proportion of the polymer. 
 
 A statistically significant decrease (P <.05, Fcrit 
(3, 20) = 3.10 and Fcal = 103.29) at the end of 
first hour, (P <.05, Fcrit (3, 20) = 3.10 and Fcal = 
302.09) at the end four hours, (P <.05, Fcrit (3, 
20) = 3.10 and Fcal = 8611.97) at the end of eight 
hours, was observed % drug release in the 
formulation KF1 to KF4, as the polymeric 
proportion increased from 40% to 70%. 
 
From the table 2, it is mentioned that the 
proposed formulations KF4 followed Higuchi 
with regression value 0.91. All formulations 
followed zero order, first order, Korsmeyer and 
Hixson Crowell with regression values between 
0.96 to 0.98, 0.94 to 0.97, 0.94 to 0.99 and 0.96 
to 0.98 respectively.  
 
Table 2: Release kinetics of formulated Ketotifen fumaratefrom different proportion of K4M CR and 
xanthan gum (3:1) based matrices. 
Code 
Zero order First order Higuchi Korsmeyer Hixson Crowell 
 
R2 K
 o % h-1 R2 K1 % h-1 R2 Kh  % h-0.5 R2 n R2 Kc  % h-1 
KF1 0.981 9.420 0.939 -0.073 0.905 27.58 0.985 0.986 0.964 0.212 
KF2 0.982 7.832 0.97 -0.051 0.893 22.77 0.965 1.019 0.978 0.159 
KF3 0.962 6.928 0.972 -0.042 0.90 20.41 0.956 1.040 0.971 0.134 
KF4 0.964 6.365 0.967 -0.037 0.888 18.62 0.943 1.049 0.967 0.120 
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Figure 2:  Successive dissolution time of Ketotifen fumarate containing various proportions of methocel K4M CR and 
xanthan gum (3:1) 
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R2, Correlation coefficients, K0, K1, Kh, Kc 
Release rate constant for zero order, first order, 
Higuchi, and Hixson Crowell release equation,  
respectively, n, diffusional exponent, indicative 
of release mechanism in Korsmeyer equation. All 
formulations followed Supper case II Release  
 
The formulation KF1 showed lowest MDT (mean 
dissolution time) with T50%, T80% values are 5.30 
hr, 5.29 hr, 8.51 respectively of all as it increased 
the release rate as containing low level of 
methocel K4M CR and xanthan gum. But, as the 
polymeric level of methocel K4M CR and 
xanthan gum is increased in the latter 
formulations (KF2, KF3 and KF4), MDT values 
were increased 6.53,7.06 and 7.82, i.e increase 
polymer viscosity increase MDT value. 
Formulation KF1 to KF4, increase polymeric 
level decrease release rate of the Ketotifen 
fumarate.  
 
T25%, T50%,  T80% and MDT values of the designed 
tablets are also shown in figure 2.  
               
Formulation KF4 containing methocel K4M CR 
and xanthan gum showed highest MDT (7.82 hr) 
value with T50% (7.89 hr), T80% (12.35 hr).  
 
The MDT (Mean Dissolution Time) values for 
the formulations KF1 to KF4 increased 
significantly P < .05, Fcrit (3, 20) = 3.10 and Fcal 
= 768.21) as polymeric level was increased from 
40% to 70%. 
 
Discussion 
Physical Evaluation of Ketotifen 
fumaratematrix tablets 
The present study was carried out to formulate 
oral sustained release drug delivery system for 
Ketotifen fumarate as matrix tablets. The drug 
content of all formulations was between 100.33% 
to 100.67 %, indicating the presence of an 
acceptable amount of drug in the formulations. 
Furthermore, all the formulations showed 
acceptable hardness and friability indicating 
suitable for direct compression method.  
 
In vitro dissolution study of tablets 
All formulations showed no evidence of initial 
burst release within the first hour of dissolution 
test period in pH 1.2 as containing polymeric 
level from 40% to 70%. However the 
formulations KF3 and KF4 containing higher 
polymeric level (60% and 70%) was increased of 
methocel K4M CR and xanthan gum polymer 
was observed more controlled within first hour 
probably to the low solubility of the drug at pH 
1.2 and higher proportion of polymer and 
retained their shape throughout the 8 hours 
dissolution period .  
 
The release rate decreased significantly and the 
drug release prolonged as the polymer proportion 
was increase. Such increase in polymer content 
results in a decrease in the drug release rate due 
to a decrease in the total porosity i.e. release is 
extended to long period. Lactose causes a 
decreased tortuosity of the path of the drug due to 
its preferential solubility than methocel K4M CR 
and xanthan gum, by its swelling effect, 
additionally weakened the integrity of the matrix 
[19].  
 
All the formulations, the rate and extent of drug 
release were decreased with increasing the 
amount of methocel K4M CR and xanthan gum. 
This polymer has been well known to retard the 
drug release by swelling in aqueous media. A 
polymer’s ability to retard the drug release rate is 
related to its viscosity. Processing factors 
including particle size, hardness, porosity and 
compressibility index etc. also can affect the 
release rate of drug from tablets [20]. The 
hydration rate of HPMC depends on the nature of 
the substituents like hydroxypropyl group 
content. Hence, Methocel K4M CR was used 
because it forms a strong viscous gel in contact 
with aqueous media, which may be useful in 
controlled delivery of drug [21]. 
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For the formulation KF3 and KF4 containing 
highest proportion of polymer and drug release is 
more controlled both pH 1.2 (less than 10% in 
first hour) and distilled water (extended more 
than 8 hours). This may be owing to a more rigid 
complex formed by presence of higher proportion 
of methocel K4M CR and xanthan gum which 
helped in retaining the drug in matrix and did not 
allow rapid diffusion of drug from the matrix. 
According to USP specification, for controlled 
release drug delivery system (Tablet/capsule), at 
time equal to 0.25D, 20 -50% drug will be 
dissolved, at time equal to 0.5D, 45-75% 
dissolved and thereafter at any time up until 
1.0D, not less than 75% of drug will be dissolved 
where D is the labeled usual dosing frequency or 
interval [22]. With this objective in view, it is 
observed that only KF3 and KF4 showed drug 
release according to USP specification. 
 
Kinetic modeling of the drug release 
The drug release data obtained were extrapolated 
by Zero order, First order, Higuchi, Korsmeyer-
Peppas and Hixson-Crowell equations to know 
the mechanism of drug release from these 
formulations. Equation (1) was used to calculate 
the n values and to identify the drug release 
mechanism of drug from the four formulations 
used in this study. 
 
 In this experiment, the in vitro release profiles of 
drug from all formulations could be best 
expressed by Zero equation as the plots showed 
highest linearity (R2: 0.96 to 0.98). To confirm 
the release mechanism, the data were fitted into 
Korsmeyer-Peppas equation. The all formulations 
showed good linearity (0.94 to 0.99) with slope 
(n) values ranging from 0.98 to 1.049 indicating 
that diffusion was the predominant mechanism of 
drug release from these formulations indicating 
that the release mechanism was supper case II 
release (n > 0.89).. It can be inferred that the 
release was dependent on Zero-order release due 
to the dissolution of polymeric matrix and 
relaxation of the polymer chain. This finding was 
also in agreement with results obtained from 
application of zero-order and Hixson-Crowell 
equations17. The good correlation coefficients (R2 
values nearly to unity) observed for the kinetic 
parameters based on the first order model 
equation were mainly due to the drug release 
mechanism. First order plot for all formulation 
showed good linearity. This indicates that the 
amount of drug released is dependent on the 
matrix drug load. The release profile of Ketotifen 
fumarate from all these formulations displayed 
very fairly good fitting with Hixson-Crowell cube 
root model of drug release confers that the drug 
releases by dissolution and with the changes in 
surface area and diameter of the particles or 
tablets [23].  
 
MDT value is used to characterize the drug 
release rate from the dosage form and the 
retarding efficacy of the polymer. A higher value 
of MDT indicates a higher drug retarding ability 
and vice-versa. The lowest MDT value (5.3 hrs) 
was found with formulation KF1 which also 
showed a low value of T50 (5.3 hrs) and a high 
value of Higuchi release rate (27.58 %/√time). In 
contrast, all other the formulations containing 
methocel K4M CR and xanthan gum exhibited a 
higher value of MDT and a low value of Higuchi 
release rate than that of batch KF1 indicating the 
higher drug-retarding ability of these 
formulations. An inverse relationship was found 
between proportion of HPMC 4000 cps and 
xanthan gum in the formulations and the MDT 
values of the dosage form. The MDT value was 
found to decrease with HPMC 4000 cps and 
xanthan gum was increased in the formulations.  
 
Conclusion 
From the study, it is possible to conclude that the 
proposed tablet formulations were suitable for 
direct compression method. According to the 
release studies, the decrease in the release rate 
was observed with an increase in the viscosity of 
the polymeric system. Polymer with higher 
proportion of methocel K4M CR and xanthan 
gum was shown to be beneficial than lower 
polymeric level in controlling drug release. The 
results of release studies indicated the possibility 
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of achieving a suitable modulation of Ketotifen 
fumarate release rate by opportunely combination 
of methocel K4M CR and xanthan gum (3:1) in 
the matrix tablet. 
 
Acknowledgement   
The authors are thankful to Colorcon Asia Pvt. 
Ltd., Bangladesh for their generous donation of 
various grades of HPMC. The authors are also 
thankful to Bangladesh University, Primeasia 
University, southeast University and the 
University of Dhaka for their supports and co-
operations. 
 
References 
1. Thomson. Micromedex. Drug Information 
for the Health Care Professional. 24th ed. 
Volume 1. Plus Updates. Content Reviewed 
by the United States Pharmacopeial 
Convention, Inc. Greenwood Village, CO. 
2004;p. 1712. 
2. Parafitt K, Martindale. The Complete Drug 
Reference, 32nd edition, London: Royal 
Pharmaceutical Society, 1999;755-756. 
3. Novartis Opthalmics. Zaditor (ketotifen 
fumarate) ophthalmic solution prescribing 
information. Duluth, GA, 2002 Oct. 
4. Tantichaiyakul P, Preutthipan A. Ketotifen 
versus inhaled budesonide for controlling 
childhood asthma. J Med Assoc Thai 2010 
may;93(5):541-9 
5. S. Budavari. The Merck Index. 12th ed. 
Whitehouse Station, NJ: Merck and Co. Inc, 
1996;p.836. 
6. Grant SM, Goa KL, Fitton A and Sorkin 
EM, Ketotifen: A Review of its 
Pharmacodynamic and Pharmacokinetic 
Properties, and Therapeutic Use in Asthma 
and Allergic Disorders. Drugs, 
1990;40:412. 
7. Blaye ILE, Donatini B, Hall M and Krupp 
P. Acute Ketotifen Overdosage A Review 
of Present Clinical Experience Drug Saf, 
1992;7:387 
8. Manuela CCM. Sobral Abilio JFN, Sobaral 
JT Guthrie and Gil MH. Ketotifen 
controlled release from cellulose acetate 
propionate and cellulose acetate butyrate 
membranes, 10 July, 2007. 
9. Sujja-areevath J, Munday DL, Cox PJ, 
Khan KA: Eur. J. Pharm. Sci, 1998;6:207. 
10. Tilak R, Kanwar M, Lal R, Gupta A.: Drug 
Dev. Ind. Pharm. 2000;26:1025. 
11. Dhopeshwarkar, V. Zatz J.L.: Drug Dev. 
Ind. Pharm. 1993:19:999. 
12. Lordi NG. Sustained release dosage form. 
In: The Theory and Practice of Industrial 
Pharmacy, 3rd Ed., Lea & Febiger, 
Philadelphia, USA, 1986;pp. 430-456. 
13. Colorcon. Methocel Literature, Oral 
Modified Release System, 
http://www.colorcon.com/pharma/mod_rel/
methocel/index.html, 2005. 
14. Sung KC, Nixon PR, Skoug JW, Roburt Ju 
T, Gao P, Topp EM and Patel MV (). 
Effects of formulation variables on drug 
and polymer release from HPMC based 
matrix tablets. Int. J. Pharm., 1996;142;53-
60. 
15. Somade S and Singh KK. Comparative 
Evaluation of Wet Granulation and Direct 
Compression Methods for Preparation of 
Controlled Release Ranitidine HCL 
Tablets,MayJune:IJPS.http://www.indianph
arma.org/journal/index.php/2002/3may%20 
%20june/comevaluation.html, 2002. 
16. Talukder MM, Michoel A, Rombaut P and 
Kinget R. Comaprative study on xanthun 
gum and hydroxypropyl methyl cellulose as 
matrices for controlled-release drug 
delivery. Int. Pharm. 1996;129:231-241. 
17. Shato H, Miyagawa, Y, Okabe T, Miyajima 
M and Sunada H. Dissolution mechanism of 
Diclofenac from wax matrix granules. J. 
Pharm. Sci.1997;86:929-934. 
18. Mockel JE, Lippold BC. Zero order release 
from hydrocolloid matrices. Pharm Res. 
1993;10:1066- 1070. 
19. Hogan J. Hydroxypropylmethylcellulose 
sustained release technology. Drug Dev 
IndPharm. 1989;15:975-999. 
20. Ebube NK, Hikal A, Wyandt CM, Beer DC, 
Miller LG, Jones AB. Sustained release of 
Rahman et al. International Journal of Drug Delivery 3 (2011) 513-524 
 
 
 
524
acetaminophen from heterogeneous matrix 
tablets, influence of polymer ratio, polymer 
loading and coactive on drugrelease. Pharm 
Dev Technol. 1997;2:161-170. 
21. Gao P, Skoug JW, Nixon PR, Ju TR, 
Stemm NL and Sung KC. Swelling  of  
hydroxypropyl  methylcellulose  tablets. 2. 
Mechanistic study of the influence of 
formulation variables on matrix 
performance and drug release, J. Pharm.  
Sci. 1996;85:732–740. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22. Banakar U. Dissolution of modified-release 
dosage forms. In: Pharmaceutical 
dissolution testing, 1st Edn., Marcel-
Dekker, Inc., New York, 1992;pp.322. 
23. Hixson AW, Crowell JH. Dependence of 
reaction velocity upon surface and 
agitation. Ind Eng Chem. 1931;23:923-931. 
